{"id":"fosamax-plus","safety":{"commonSideEffects":[{"rate":"5-15%","effect":"Gastrointestinal upset (nausea, dyspepsia, abdominal pain)"},{"rate":"5-10%","effect":"Musculoskeletal pain"},{"rate":"3-5%","effect":"Headache"},{"rate":"1-3%","effect":"Esophageal irritation"},{"rate":"rare","effect":"Hypocalcemia"}]},"_chembl":{"chemblId":"CHEMBL870","moleculeType":"Small molecule","molecularWeight":"249.10"},"_dailymed":{"setId":"10307e7e-9a84-4aa1-8c5c-4b209cffe4d1","title":"FOSAMAX PLUS D (ALENDRONATE SODIUM AND CHOLECALCIFEROL) TABLET [ORGANON LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Alendronate works by binding to hydroxyapatite in bone and inhibiting osteoclast-mediated bone resorption, slowing bone loss. Cholecalciferol supplementation enhances intestinal calcium absorption and supports bone mineralization. Together, these components reduce fracture risk in osteoporosis by maintaining or increasing bone mineral density.","oneSentence":"FOSAMAX PLUS combines alendronate (a bisphosphonate) with cholecalciferol (vitamin D3) to inhibit bone resorption and improve calcium absorption.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:32:42.191Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis in postmenopausal women"},{"name":"Osteoporosis in men"},{"name":"Glucocorticoid-induced osteoporosis"}]},"trialDetails":[{"nctId":"NCT07471880","phase":"PHASE2","title":"A Phase II Trial of RAB001 (LLP2A-Alendronate) for Steroid-Induced Early-Stage Osteonecrosis of the Femoral Head","status":"ACTIVE_NOT_RECRUITING","sponsor":"ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd.","startDate":"2024-12-24","conditions":"Osteonecrosis, Osteonecrosis of the Femoral Head","enrollment":161},{"nctId":"NCT06973109","phase":"PHASE2","title":"Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes","status":"NOT_YET_RECRUITING","sponsor":"Nitin Agarwal","startDate":"2026-03-20","conditions":"Osteoporosis, Post-menopausal","enrollment":36},{"nctId":"NCT07435051","phase":"PHASE3","title":"Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cierny-Mader Type I and III Osteomyelitis","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-05-01","conditions":"Osteomyelitis (Refractory)","enrollment":280},{"nctId":"NCT06016634","phase":"PHASE2","title":"Alendronate for Osteonecrosis in Adults With Sickle Cell Disease","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2026-02-09","conditions":"Sickle Cell Disease, Sickle Cell Anemia, Osteonecrosis","enrollment":30},{"nctId":"NCT05764733","phase":"PHASE4","title":"Bone, Exercise, Alendronate, and Caloric Restriction","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2023-06-08","conditions":"Bone Loss","enrollment":900},{"nctId":"NCT07245381","phase":"PHASE1, PHASE2","title":"Alendronate to Reduce Pelvic Insufficiency Fractures in Cervical Cancer Patients Undergoing Chemoradiation","status":"NOT_YET_RECRUITING","sponsor":"Dr. Itay GoorAryeh","startDate":"2025-12","conditions":"Cervix Cancer","enrollment":65},{"nctId":"NCT07242612","phase":"NA","title":"Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis","status":"RECRUITING","sponsor":"Khyber Medical University Peshawar","startDate":"2025-10-01","conditions":"Osteoporosis, Osteoporosis, Postmenopausal","enrollment":40},{"nctId":"NCT03292146","phase":"PHASE3","title":"Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-10-25","conditions":"Bone Density, Bone Loss, Anorexia Nervosa","enrollment":30},{"nctId":"NCT04708886","phase":"PHASE2","title":"Romosozumab in Women With Chronic SCI","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2021-03-01","conditions":"Osteoporosis, Bone Loss, Osteopenia, Osteoporosis","enrollment":12},{"nctId":"NCT01648686","phase":"NA","title":"Bone Healing After Dental Extraction in Postmenopausal Osteoporotic Women Treated With Alendronate Per os Weekly","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-09-19","conditions":"Alveolar Bone Healing After Dental Extraction","enrollment":66},{"nctId":"NCT05493761","phase":"PHASE4","title":"Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aristotle University Of Thessaloniki","startDate":"2022-12-23","conditions":"Nonalcoholic Fatty Liver, Osteoporosis, Postmenopausal","enrollment":72},{"nctId":"NCT07028320","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk","status":"COMPLETED","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2021-12-03","conditions":"Postmenopausal Women With Osteoporosis","enrollment":493},{"nctId":"NCT05575167","phase":"","title":"Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)","status":"RECRUITING","sponsor":"424 General Military Hospital","startDate":"2023-11-28","conditions":"Osteoporosis, Postmenopausal","enrollment":125},{"nctId":"NCT05151484","phase":"PHASE4","title":"Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover","status":"RECRUITING","sponsor":"Madhumathi Rao","startDate":"2022-03-21","conditions":"Age-Related Osteoporosis","enrollment":60},{"nctId":"NCT06864130","phase":"PHASE4","title":"A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women With Osteoporosis After a Treatment Period Without Fractures","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2025-02-21","conditions":"Osteoporosis in Post-menopausal Women","enrollment":1400},{"nctId":"NCT06856369","phase":"PHASE4","title":"Clinical Efficacy of 1% Metformin and Alendronate Gel in Adjunct to Fibrin in Chronic Periodontitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bahria University","startDate":"2025-01-22","conditions":"Alveolar Bone Loss Associated Chronic Periodontitis","enrollment":120},{"nctId":"NCT01631214","phase":"PHASE3","title":"Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-05-04","conditions":"Postmenopausal Women With Osteoporosis","enrollment":4093},{"nctId":"NCT06772792","phase":"PHASE1","title":"A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-23","conditions":"Healthy","enrollment":36},{"nctId":"NCT04338529","phase":"","title":"Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation","status":"COMPLETED","sponsor":"251 Hellenic Air Force & VA General Hospital","startDate":"2020-04-01","conditions":"Postmenopausal Osteoporosis","enrollment":92},{"nctId":"NCT02520362","phase":"","title":"Denosumab Safety Assessment in Multiple Observational Databases","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-05-31","conditions":"Osteoporosis","enrollment":517991},{"nctId":"NCT06621069","phase":"","title":"The Effect of Long-term Use of Bisphosphonates on Femur Morphology","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-06-01","conditions":"Osteoporosis, Knee Osteoarthristis","enrollment":140},{"nctId":"NCT05602493","phase":"PHASE3","title":"A Randomized Control Trial Phase (IIIa) Unicentric, Placebo Controlled, Double-Blinded Efficacy and Safety of Topical Alendronic Acid on Alveolar Bone Remodeling After Tooth Extraction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xeolas Pharmaceuticals Limited","startDate":"2022-11-22","conditions":"Bone Loss, Alveolar","enrollment":60},{"nctId":"NCT00092040","phase":"PHASE3","title":"A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-03-18","conditions":"Osteoporosis, Postmenopausal","enrollment":936},{"nctId":"NCT00092066","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-09-24","conditions":"Osteoporosis, Vitamin D Deficiency","enrollment":717},{"nctId":"NCT00480662","phase":"PHASE3","title":"A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-10","conditions":"Paget's Disease of Bone","enrollment":60},{"nctId":"NCT00092014","phase":"PHASE3","title":"A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-09-01","conditions":"Postmenopausal Osteoporosis","enrollment":1053},{"nctId":"NCT00389740","phase":"PHASE3","title":"A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-04-02","conditions":"Osteoporosis, Postmenopausal","enrollment":400},{"nctId":"NCT06264401","phase":"NA","title":"Treatment Exercises With Core Stability and Dynamic Resistance Exercise for Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Cairo University","startDate":"2024-02-01","conditions":"Postmenopausal Osteoporosis","enrollment":60},{"nctId":"NCT03542695","phase":"EARLY_PHASE1","title":"64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2021-11-03","conditions":"Breast Carcinoma, Calcification","enrollment":1},{"nctId":"NCT01350934","phase":"PHASE4","title":"A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-06-19","conditions":"Osteoporosis, Postmenopausal","enrollment":219},{"nctId":"NCT00692913","phase":"PHASE3","title":"A Study to Test the Effect of MK0217A on Vitamin D Inadequacy in Postmenopausal Women With Osteoporosis (0217A-262)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-06","conditions":"Osteoporosis","enrollment":515},{"nctId":"NCT03396315","phase":"PHASE2","title":"Bisphosphonates for Prevention of Post-Denosumab Bone Loss","status":"COMPLETED","sponsor":"Columbia University","startDate":"2018-01-29","conditions":"IOP, Osteoporosis","enrollment":24},{"nctId":"NCT00729651","phase":"PHASE4","title":"Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-03-20","conditions":"Osteoporosis Postmenopausal","enrollment":343},{"nctId":"NCT01437111","phase":"PHASE3","title":"Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-10-26","conditions":"Osteoporosis","enrollment":200},{"nctId":"NCT00019695","phase":"PHASE2","title":"Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-03","conditions":"Stage IV Prostate Cancer, Bone Metastases, Adenocarcinoma of the Prostate","enrollment":""},{"nctId":"NCT02944799","phase":"PHASE2","title":"Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2015-12","conditions":"Rheumatoid Arthritis, Osteoporosis","enrollment":69},{"nctId":"NCT04555317","phase":"NA","title":"Bone Toxicity Following Pelvic Radiotherapy","status":"UNKNOWN","sponsor":"The Christie NHS Foundation Trust","startDate":"2021-05-17","conditions":"Gynecologic Cancer, Radiotherapy Side Effect, Fracture","enrollment":80},{"nctId":"NCT00580047","phase":"NA","title":"Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2003-12-01","conditions":"Renal Insufficiency","enrollment":59},{"nctId":"NCT02195895","phase":"PHASE2","title":"Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2014-04","conditions":"Spinal Cord Injury, Bone Loss, Osteoporosis","enrollment":17},{"nctId":"NCT05662358","phase":"NA","title":"Denosumab vs Alendronate After Vertebroplasty","status":"UNKNOWN","sponsor":"Shenzhen People's Hospital","startDate":"2021-01-03","conditions":"Denosumab Allergy","enrollment":90},{"nctId":"NCT01875458","phase":"","title":"Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2012-04-13","conditions":"Osteoporosis, With or Without Treatment, Bisphosphonate Treatment, Atypical Femur Fracture","enrollment":314},{"nctId":"NCT02440581","phase":"NA","title":"Renal Osteodystrophy: An Individual Management Approach","status":"COMPLETED","sponsor":"Hartmut Malluche, MD","startDate":"2015-07-01","conditions":"Kidney Failure, Chronic","enrollment":141},{"nctId":"NCT05645289","phase":"PHASE4","title":"Efficacy and Safety of Minodronate in Patients With Low Back Pain","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2023-01-01","conditions":"Postmenopausal Osteoporosis","enrollment":72},{"nctId":"NCT00896532","phase":"PHASE2","title":"Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-06-03","conditions":"Low Bone Mineral Density, Postmenopausal Osteoporosis","enrollment":419},{"nctId":"NCT05397938","phase":"PHASE2","title":"Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis","status":"UNKNOWN","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2022-06-15","conditions":"Glucocorticoid Induced Osteoporosis","enrollment":231},{"nctId":"NCT05387200","phase":"PHASE4","title":"Phase IV Clinical Trial to Evaluate Efficacy and Safety of MASI BONE S (Alendronate Sodium Trihydrate) in Postmenopausal Women With Osteoporosis","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2021-07-02","conditions":"Osteoporosis","enrollment":170},{"nctId":"NCT02322099","phase":"PHASE4","title":"Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss","status":"TERMINATED","sponsor":"University College Dublin","startDate":"2016-05","conditions":"Bone Demineralization","enrollment":53},{"nctId":"NCT05305183","phase":"PHASE3","title":"A Phase III Clinical Study of Minodronate Tablets in Postmenopausal Women With Osteoporosis","status":"UNKNOWN","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2022-05-31","conditions":"Osteoporosis","enrollment":330},{"nctId":"NCT00806416","phase":"PHASE1","title":"A Study of the Bioequivalence of 70 mg Alendronate and 70 mg Alendronate in Combination With 2800 IU Vitamin D","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-05","conditions":"Osteoporosis","enrollment":244},{"nctId":"NCT01065779","phase":"","title":"FOSAMAX PLUS and FOSAMAX PLUS D Re-examination Study (0217A-267)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-03","conditions":"Osteoporosis","enrollment":880},{"nctId":"NCT00803790","phase":"PHASE1","title":"A Study of the Bioequivalence of 70-mg Alendronate and 70-mg Alendronate in Combination With 5600 IU Vitamin D (MK0217A-253)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-05","conditions":"Osteoporosis","enrollment":318},{"nctId":"NCT00398931","phase":"PHASE3","title":"FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1998-02","conditions":"Osteoporosis, Postmenopausal","enrollment":1099},{"nctId":"NCT00398606","phase":"PHASE3","title":"A Study to Compare the Efficacy of Alendronate With and Without Calcium or Calcium Alone In the Treatment of Osteoporosis in Postmenopausal Women (0217-088)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1995-04","conditions":"Osteoporosis, Postmenopausal","enrollment":650},{"nctId":"NCT01077817","phase":"","title":"Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-02-26","conditions":"Esophageal Cancer, Squamous Cell Carcinoma, Adenocarcinoma","enrollment":684815},{"nctId":"NCT00641771","phase":"PHASE1","title":"4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-05","conditions":"Osteoporosis","enrollment":56},{"nctId":"NCT05162885","phase":"EARLY_PHASE1","title":"Effect of Sodium Alendronate on the Final Implant Stability.","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2021-05-01","conditions":"Anterior Labial Wall Defect","enrollment":24},{"nctId":"NCT02304757","phase":"NA","title":"99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis","status":"COMPLETED","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2015-01","conditions":"Differentiated Thyroid Cancer, Osteoporosis","enrollment":142},{"nctId":"NCT04169698","phase":"PHASE2, PHASE3","title":"Alendronate Versus Denosumab in Kidney Transplant Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2019-10-17","conditions":"Osteoporosis, Osteopenia, Renal Transplant Recipient","enrollment":90},{"nctId":"NCT00921557","phase":"PHASE2","title":"Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-11","conditions":"HIV Infection","enrollment":52},{"nctId":"NCT02371252","phase":"PHASE4","title":"Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2014-04","conditions":"Osteoporosis","enrollment":140},{"nctId":"NCT03197623","phase":"PHASE1","title":"Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids","status":"COMPLETED","sponsor":"Nancy E. Lane, MD","startDate":"2016-10-14","conditions":"Osteopenia, Osteoporosis, Osteonecrosis","enrollment":58},{"nctId":"NCT04861142","phase":"","title":"Osteoporosis Treatment Protocol in Patients With Fragility Fractures: Application and Efficacy","status":"UNKNOWN","sponsor":"University General Hospital of Heraklion","startDate":"2021-04-23","conditions":"Osteoporosis","enrollment":350},{"nctId":"NCT03051620","phase":"","title":"Predictive Value of Bone Turnover Markers During Discontinuation With Alendronate","status":"COMPLETED","sponsor":"Aarhus University Hospital","startDate":"2017-02-01","conditions":"Osteoporosis","enrollment":142},{"nctId":"NCT04719572","phase":"NA","title":"Intervention Study of Drugs in Patients Osteopenia and Osteoporosis","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2021-03","conditions":"Osteoporosis, Osteopenia, Osteoporosis","enrollment":180},{"nctId":"NCT04704947","phase":"PHASE3","title":"Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis","status":"RECRUITING","sponsor":"Sherief Abd-Elsalam","startDate":"2017-10-01","conditions":"Beta Blocker Toxicity","enrollment":50},{"nctId":"NCT01657162","phase":"PHASE3","title":"Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis","status":"COMPLETED","sponsor":"Radius Health, Inc.","startDate":"2012-11-20","conditions":"Postmenopausal Osteoporosis","enrollment":1139},{"nctId":"NCT03435094","phase":"","title":"Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes","status":"UNKNOWN","sponsor":"Labatec Pharma SA","startDate":"2018-02-25","conditions":"Osteoporosis, Postmenopausal","enrollment":80},{"nctId":"NCT00354302","phase":"PHASE3","title":"Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2006-04-24","conditions":"Breast Cancer, Osteoporosis","enrollment":497},{"nctId":"NCT00421343","phase":"PHASE3","title":"Secondary Prevention of Osteoporosis","status":"COMPLETED","sponsor":"Hebrew SeniorLife","startDate":"2007-02","conditions":"Osteoporosis","enrollment":29},{"nctId":"NCT00518531","phase":"PHASE3","title":"Denosumab Adherence Preference Satisfaction Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-09-01","conditions":"Osteoporosis","enrollment":250},{"nctId":"NCT04140006","phase":"PHASE1, PHASE2","title":"Efficacy of Antiresorptive and Bone Forming Material on Dental Implants","status":"UNKNOWN","sponsor":"University of Baghdad","startDate":"2019-07-01","conditions":"Partial Edentulism","enrollment":20},{"nctId":"NCT03980847","phase":"PHASE2","title":"Evaluation, the Histomorphometric Study of Nanocrystalline Hydroxyapatite (Nano Bone) Wif Alendronate in the Preservation of the Tooth Socket","status":"COMPLETED","sponsor":"Islamic Azad University, Sanandaj","startDate":"2018-02-23","conditions":"Bone Resorption","enrollment":20},{"nctId":"NCT01588509","phase":"PHASE1","title":"Transition From Alendronate to Romosozumab (AMG 785)","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-03-30","conditions":"Osteoporosis","enrollment":60},{"nctId":"NCT01406613","phase":"","title":"Resolution of Effect of Bisphosphonates on Bone in Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2010-03","conditions":"Postmenopausal Osteoporosis","enrollment":86},{"nctId":"NCT01512446","phase":"PHASE3","title":"Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy","status":"TERMINATED","sponsor":"Evangelisches Krankenhaus Lutherhaus gGmbH","startDate":"2012-02","conditions":"Osteoporosis","enrollment":436},{"nctId":"NCT03006003","phase":"PHASE4","title":"Osteoporosis Treatment in Post-menopausal Women","status":"UNKNOWN","sponsor":"Taichung Veterans General Hospital","startDate":"2017-01-01","conditions":"Depressive Syndrome","enrollment":500},{"nctId":"NCT03692143","phase":"","title":"Comparation of Treatment Strategies for OVF: Teriparatide Injection and PVP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2017-01-01","conditions":"Osteoporosis, Postmenopausal, Vertebral Fracture, Quality of Life","enrollment":90},{"nctId":"NCT00145977","phase":"NA","title":"Texture Analysis for Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2001-07","conditions":"Osteoporosis, Osteopenia","enrollment":36},{"nctId":"NCT01101048","phase":"PHASE1","title":"An Ascending Multiple Dose Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-06","conditions":"Osteopenia","enrollment":74},{"nctId":"NCT00885170","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-13","conditions":"Osteoporosis","enrollment":246},{"nctId":"NCT00920075","phase":"","title":"Alendronate in Juvenile Osteoporosis","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2009-07","conditions":"Juvenile Osteoporosis, Low Bone Density, Fractures","enrollment":11},{"nctId":"NCT01968850","phase":"PHASE2","title":"Bone Antiresorptive Therapy With Antiretroviral Initiation (BATARI) Pilot Trial","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2014-04-23","conditions":"HIV","enrollment":30},{"nctId":"NCT02645799","phase":"PHASE2","title":"BLADE-PCI Trial (BLADE); PHASE IIB LIPOSOMAL ALENDRONATE STUDY","status":"UNKNOWN","sponsor":"BIOrest Ltd.","startDate":"2016-04","conditions":"Diabetes Mellitus","enrollment":270},{"nctId":"NCT01882400","phase":"PHASE4","title":"Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy","status":"COMPLETED","sponsor":"Gilles Boire","startDate":"2001-05","conditions":"Osteoporosis, Muscular Dystrophy, Cystic Fibrosis","enrollment":11},{"nctId":"NCT00471237","phase":"PHASE2","title":"A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2007-05-14","conditions":"Osteoporosis","enrollment":564},{"nctId":"NCT00668941","phase":"PHASE2","title":"Cyclic Versus Daily Teriparatide on Bone Mass","status":"UNKNOWN","sponsor":"Helen Hayes Hospital","startDate":"2005-09","conditions":"Osteoporosis","enrollment":140},{"nctId":"NCT00006180","phase":"PHASE4","title":"Bone Loss in Premenopausal Women With Depression","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2000-08-10","conditions":"Depression, Healthy, Osteopenia","enrollment":220},{"nctId":"NCT03204097","phase":"PHASE2, PHASE3","title":"Local Host Modulating Agents Alendronate & Aloe Vera for Treatment of Furcation Defects in Chronic Periodontitis","status":"COMPLETED","sponsor":"Government Dental College and Research Institute, Bangalore","startDate":"2016-03","conditions":"Chronic Periodontitis","enrollment":90},{"nctId":"NCT01750086","phase":"PHASE4","title":"Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2013-01","conditions":"Postmenopausal Osteoporosis","enrollment":27},{"nctId":"NCT02598453","phase":"PHASE4","title":"PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-01","conditions":"Postmenopausal Osteoporosis","enrollment":545},{"nctId":"NCT02604836","phase":"PHASE4","title":"A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-06","conditions":"Postmenopausal Osteoporosis","enrollment":1711},{"nctId":"NCT02598440","phase":"PHASE4","title":"A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-03","conditions":"Postmenopausal Osteoporosis","enrollment":341},{"nctId":"NCT01128257","phase":"","title":"A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-04","conditions":"Postmenopausal Osteoporosis","enrollment":6054},{"nctId":"NCT00545779","phase":"PHASE3","title":"BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-12","conditions":"Post-Menopausal Osteoporosis","enrollment":677},{"nctId":"NCT02166437","phase":"","title":"Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese","status":"UNKNOWN","sponsor":"Tomidahama Hospital","startDate":"2013-11","conditions":"Osteoporosis","enrollment":500},{"nctId":"NCT00001720","phase":"PHASE2","title":"Treatment of Childhood Osteoporosis With Alendronate (Fosamax)","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"1998-03","conditions":"Osteoporosis","enrollment":50},{"nctId":"NCT01104987","phase":"","title":"Treatment With Alendronate in Patients With Ankylosing Spondylitis (AS)","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2009-10","conditions":"Ankylosing Spondylitis, Osteoporosis","enrollment":16},{"nctId":"NCT02795546","phase":"PHASE4","title":"Effect of Alendronate With β - TCP Bone Substitute in Surgical Therapy of Periodontal Intra-osseous Defects.","status":"COMPLETED","sponsor":"Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre","startDate":"2015-01","conditions":"Intrabony Periodontal Defect","enrollment":32},{"nctId":"NCT00996801","phase":"PHASE2","title":"MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"Osteoporosis, Postmenopausal Osteoporosis","enrollment":526},{"nctId":"NCT00739466","phase":"PHASE2","title":"Biorest Liposomal Alendronate With Stenting sTudy (BLAST)","status":"COMPLETED","sponsor":"BIOrest Ltd.","startDate":"2008-09","conditions":"Coronary Artery Stenosis","enrollment":226}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"20070426","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20100301","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20061228","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20260203","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20150710","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20130419","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20100301","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20110701","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20151130","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20110125","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20100301","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20050407","type":"ORIG","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20061228","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20051102","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20131107","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20190816","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20150408","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20081008","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"}],"publicationCount":251,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"FOSAMAX PLUS","genericName":"FOSAMAX PLUS","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOSAMAX PLUS combines alendronate (a bisphosphonate) with cholecalciferol (vitamin D3) to inhibit bone resorption and improve calcium absorption. Used for Osteoporosis in postmenopausal women, Osteoporosis in men, Glucocorticoid-induced osteoporosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}